CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). This study will also all...
Phase 1
Rochester, Minnesota, United States and 17 other locations
Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia...
Phase 2
Rochester, Minnesota, United States and 7 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Rochester, Minnesota, United States and 130 other locations
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia...
Phase 3
Rochester, Minnesota, United States and 83 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Rochester, Minnesota, United States and 67 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Rochester, Minnesota, United States and 216 other locations
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia...
Phase 1
Rochester, Minnesota, United States and 11 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...
Phase 1, Phase 2
Rochester, Minnesota, United States and 55 other locations
with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectiv...
Phase 3
Rochester, Minnesota, United States and 154 other locations
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in select...
Phase 1, Phase 2
Rochester, Minnesota, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal